Complex diagnostic and treatment issues in psychotic symptoms associated with narcolepsy

Psychiatry

Volumn 6, Issue 6, 2009, Pages 38-44

  Moturi, Sricharan ^a   Ivanenko, Anna ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b CENTRAL DUPAGE HOSPITAL   (United States)

Author keywords

Antipsychotics; Comorbidity; Narcolepsy; Psychosis; Stimulants

Indexed keywords

ARIPIPRAZOLE; ARMODAFINIL; CENTRAL STIMULANT AGENT; CLOZAPINE; HLA DQ ANTIGEN; HLA DQ1 ANTIGEN; HLA DQ6 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR15 ANTIGEN; MODAFINIL; NEUROLEPTIC AGENT; OREXIN; OXYBATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; HLA TYPING; HUMAN; LOW DRUG DOSE; MANIA; NARCOLEPSY; PREVALENCE; PROTEIN BLOOD LEVEL; PSYCHOSIS; REM SLEEP; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT RESPONSE; VISUAL HALLUCINATION;

EID: 68449102095     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Douglass AB, Hays P, Pazderka F, et al. Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis. 1991;179(1):12-17.
2. Stores G. The protean manifestations of childhood narcolepsy and their misinterpretation. Dev Med Child Neurol. 2006;48(4):307-310
3. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep. 1994;17(8 Suppl):S45-49
4. Macleod S, Ferrie C, Zuberi SM. Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord. 2005;7(1):13-17.
5. Oosterloo M, Lammers GJ, Overeem S, et al. Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder. Psychiatry Res. 2006;30;143(2-3):293-297.
6. Szucs A, Janszky J, Hollo A, et al. Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand. 2003;108(4):314-316
7. Kales A, Kales JD. Sleep disorders. Recent findings in the diagnosis and treatment of disturbed sleep. N Engl J Med. 197428;290(9):487-499
8. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol. 2003;53(2):154-166
9. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8(4):373-399
10. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;11;57(11):2029-2033
11. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-474
12. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Second Edition. Westchester, NY: American Academy of Sleep Medicine, 2005.
13. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology. 2001;26;57(12):2253-2258
14. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-1562
15. Kondziella D, Arlien-Soborg P. Diagnostic and therapeutic challenges in narcolepsy-related psychosis. J Clin Psychiatry. 2006;67(11):1817-1819
16. Kishi Y, Konishi S, Koizumi S, et al. Schizophrenia and narcolepsy: a review with a case report. Psychiatry Clin Neurosci. 2004;58(2):117-124.
17. Bhat SK, Galang R. Narcolepsy presenting as schizophrenia. Am J Psychiatry. 2002;159(7):1245.
18. Vourdas A, Shneerson JM, Gregory CA, et al. Narcolepsy and psychopathology: is there an association? Sleep Med. 2002;3(4):353-360
19. Takeuchi N, Mukai M, Uchimura N, et al. A narcoleptic patient exhibiting hallucinations and delusion. Psychiatry Clin Neurosci. 2000;54(3):321-322
20. Shapiro B, Spitz H. Problems in the differential diagnosis of narcolepsy versus schizophrenia. Am J Psychiatry. 1976;133:1321-1323
21. McNally RJ, Clancy SA. Sleep paralysis, sexual abuse, and space alien abduction. Transcult Psychiatry. 2005;42(1):113-122
22. Douglass AB, Shipley JE, Haines RF, et al. Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol Psychiatry. 1993;34(11):773-780
23. Stores G. Sleep paralysis and hallucinosis. Behav Neurol.1998;11:109-112.
24. Philippe A, Deron J, Geneviève D, et al. Neurodevelopmental pattern of succinic semialdehyde dehydrogenase deficiency(gamma-hydroxybutyric aciduria). Dev Med Child Neurol. 2004; 46(8):564-568.
25. Walterfang M, Upjohn E, Velakoulis D. Is schizophrenia associated with narcolepsy? Cogn Behav Neurol. 2005;18(2):113-118
26. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149-1152
27. Mosholder AD, Gelperin K, Hammad TA, et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/ hyperactivity disorder drugs in children. Pediatrics. 2009;123(2):611-616.
28. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006;101(Suppl 1):76-88
29. Auger RR, Goodman SH, Silber M. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study. Sleep. 2005;28(6):667-672
30. Pawluk LK, Hurwitz TD, Schluter JL, et al. Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. J Nerv Ment Dis. 1995;183(1):45-48
31. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158(8):1206-1214
32. Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 2006;8(2):E413-418
33. Chen CK, Lin SK, Sham PC, et al. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2005;136B(1):87-91
34. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407-1414
35. Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009;14(2):123-142. Epub 2008 Aug 12
36. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196-204
37. Dahmen N, Kasten M, Mittag K, Müller MJ. Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology. Eur J Health Econ. 2002;3(Suppl 2):S94-98
38. Fortuyn HA, Lappenschaar GA, Nienhuis FJ, et al. Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry. 2009;31(2):146-154.
39. Van den Hoed J, Lucas EA, Dement WC. Hallucinatory experiences during cataplexy in patients with narcolepsy. Am J Psychiatry. 1979;136:1210-1211
40. Krishnan RR, Volow MR, Cavenar JO Jr, Miller PP. Dreams of flying in narcoleptic patients. Psychosomatics. 1984;25(5):423-425.
41. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-1711.
42. Trzepacz PT. Concurrent narcolepsy and bipolar affective disorder. Psychosomatics. 1987;28(4):219-221
43. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 200667(4):554-566
44. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561-569
45. Vorspan F, Warot D, Consoli A, et al. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry. 2005;162(4):813-814
46. Fountoulakis KN, Siamouli M, Panagiotidis P, et al. Ultra short manic-like episodes after antidepressant augmentation with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):891-892
47. Narendran R, Young CM, Valenti AM, et al. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry. 2002;59:292-293
48. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761-774.
49. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007;11(2):113-133. Epub 2007 Feb 1
50. Keshavan MS, Prasad KM, Montrose DM, et al. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. J Clin Psychopharmacol. 2007;27(6):703-705.
51. Sharpley AL, Bhagwagar Z, Hafizi S, et al. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry. 2003;64(2):192-196.
52. Barnas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry. 2005;66(10):1339
53. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol. 2004;19(1):45-48
54. Desarkar P, Goyal N, Khess CR. Clozapine-induced cataplexy. J Neuropsychiatry Clin Neurosci. 2007;19(1):87-88
55. Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs. 2007;21(4):337-354
56. The Xyrem® International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005 Oct 15;1(4):391-397
57. Snead OC III, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005;352(26):2721-2732
58. Borgland SL, Taha SA, Sarti F, et al. Orexin A in the VTA is critical for the induction of synaptic plasticity andbehavioral sensitization to cocaine. Neuron. 2006;49:589-601.
59. Narita M, Nagumo Y, Hashimoto S, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci. 2006;26(2):398-405
60. Lawrence AJ, Cowen MS, Yang HJ, et al. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006;148(6):752-759. Epub 2006 Jun 5
61. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Saf. 2004;27(5):293-306
62. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23(1):45-49.